Cancer cells acquire characteristics of deregulated growth, survival and increased metastatic potential. Genetic mutations that provide a selective advantage by promoting these characteristics have been termed 'drivers,' whereas mutations that do not contribute to disease initiation/progression are termed 'passengers.' The advent of high-throughput methodologies has facilitated large-scale screening of cancer genomes and the subsequent identification of novel somatic mutations. Although this approach has generated valuable results, the data remain incomplete until the functional consequences of these mutations are determined to differentiate potential drivers from passengers. ROCK1 is an essential effector kinase downstream of Rho GTPases, an important pathway involved in cell migration. The Cancer Genome Project identified three nonsynonymous mutations in the ROCK1 gene. We now show that these somatic ROCK1 mutations lead to elevated kinase activity and drive actin cytoskeleton rearrangements that promote increased motility and decreased adhesion, characteristics of cancer progression. Mapping of the kinase-interacting regions of the carboxy terminus combined with structural modeling provides an insight into how these mutations likely affect the regulation of ROCK1. Consistent with the frequency of ROCK1 mutations in human cancer, these results support the conclusion that there is selective pressure for the ROCK1 gene to acquire 'driver' mutations that result in kinase activation.
The identification of mutated genes that drive human oncogenesis is an ongoing major objective worldwide. The development of high-throughput detection methodologies has facilitated the identification of novel somatic mutations associated with numerous cancers (http://www.sanger.ac.uk/genetics/CGP/ and http://cancergenome.nih.gov/). Statistical analysis of mutation frequencies can be used to classify them as active 'driver' mutations that provide a selective advantage during cancer initiation and progression, or silent 'passengers,' which are expanded from progenitor cells, yet provide no overt selective advantage. Although this approach has tremendous value in identifying important genes in cancer, it remains incomplete until the biological consequences of detected mutations are determined to differentiate drivers from passengers.
Cancer genome sequencing has revealed three novel ROCK1 mutations in human malignant disease (http:// www.sanger.ac.uk/cgi-bin/genetics/CGP/cosmicsearch?_ q ¼ rock1). The three somatic mutations in ROCK1 are: AA insertion between base pair (bp) 1214-1215, resulting in frameshift and premature termination at Y405*; C to G transition at bp 3377, resulting in premature termination at S1126*; and C to T transversion at bp 3577, resulting in the amino-acid substitution P1193S (Figure 1a ). The Y405* and S1126* mutants were both identified in primary human breast cancers, whereas the third mutation, P1193S, was identified from the established human non-small-cell lung carcinoma line NCI-H1770 (Greenman et al., 2007) .
ROCK1 and ROCK2 (Rho-associated kinases 1 and 2) are significant effector kinases of the small GTPase RhoA (Olson and Sahai, 2009 ). The primary function of this pathway is the generation of acto-myosin contractile force, which influences behaviors including motility, survival and proliferation. There is a wealth of data implicating Rho GTPases in human cancer (Sahai and Marshall, 2002; Benitah et al., 2004) further suggesting that ROCK1 and ROCK2, as key mediators of Rho signaling, may have important roles (Narumiya et al., 2009) . In support of this, preclinical studies have shown beneficial effects of ROCK inhibition on tumor incidence rates, volume, invasiveness and metastasis (Itoh et al., 1999; Somlyo et al., 2000; Nakajima et al., 2003; Ying et al., 2006; Ogawa et al., 2007; Xue et al., 2008) . In addition, elevated ROCK1 and/or ROCK2 expression have been detected in several human cancers, which correlated with poor outcome (Kamai et al., 2002 (Kamai et al., , 2003 (Kamai et al., , 2004 Abe et al., 2008) . Although alterations in the regulation of ROCK1 signaling as an important contributory factor to human cancer may be well accepted, this is the first report of ROCK1 activation as a direct consequence of somatic mutations. In this study, we describe the biochemical and biological activities of these mutants and conclude that these ROCK1 mutations are activating. These observations are consistent with the statistical analysis of nonsynonymous versus synonymous mutation rates, which indicates that the ROCK1 gene is under positive selection pressure as a cancer driver (Greenman et al., 2007) To determine how these mutations affected ROCK1 activity, MYC-tagged wild type (WT), kinase-dead K105G, and Y405*, S1126* and P1193S proteins were expressed in NIH 3T3 mouse fibroblast cells. WT, K105G and P1193S migrated at 158 kDa, whereas Y405* and S1126* migrated as expected at 47 and 113 kDa, respectively, as determined by western blotting (Figure 1b) . In vitro kinase assays of the MYCimmunoprecipitated proteins revealed that the activity of all three ROCK1 mutants was increased significantly (2.5-to 3.5-fold) relative to WT. The kinase-dead K105G mutant had no detectable activity, indicating that the active forms possessed intrinsic kinase activity that did not result from contaminating MYC-tag coimmunoprecipitating kinases (Figure 1b) . We next determined whether ROCK1 mutants that retained the Rho-binding domain could be further activated by GTP-loaded RhoA. Consistent with previous results, WT ROCK1 was significantly activated fourfold by RhoA-GTP (Matsui et al., 1996) , S1126* activity was not increased and P1193S was marginally elevated but failed to achieve statistical significance. Nonetheless, neither mutant was activated to a greater degree than WT, indicating that the ROCK1 mutations do not enhance RhoA-GTP-induced activation. In addition, expression of Y405*, S1126* and P1193S mutants in NIH 3T3 fibroblasts stimulated actin stress fiber formation and increased myosin light chain phosphorylation on serine19 (Figure 1d ), two hallmarks of ROCK activity in cells. These results show that the novel ROCK1 somatic mutations identified from human cancers have enhanced activity in vitro and in cells.
Given the prominent role of ROCK1 in tumor cell invasion and metastasis (Olson and Sahai, 2009) , we assessed the effects of the somatic ROCK1 mutations on cell morphology, motility and adhesion. Expression of the MYC-tagged ROCK1 proteins in NIH 3T3 fibroblasts, assessed by flow cytometry, was comparable for WT, S1126* and P1193S, whereas expression of K105G and Y405* was lower (Supplemental Figures 1a  and b) . Within 6 h of transfection, the active ROCK1 mutants Y405*, S1126* and P1193S induced cellular contraction, significantly reducing the mean area per cell (Figure 2a ). No differences in subcellular localization of the ROCK1 mutants compared with WT were observed (data not shown). When the effects of the active ROCK1 mutants on cell morphology were examined, Y405*, S1126* and P1193S expression markedly modified cell shape, shifting the distribution of morphologies from predominant spread to contracted and rounded (Figure 2b) . Consistent with the effects on cell contraction, analysis of individual random cell motility by timelapse microscopy revealed that S1126*-and P1193S-expressing NIH 3T3 cells were more motile than GFPexpressing control cells, with significantly longer cumulative track lengths (Figure 2c ). Although track lengths of WT ROCK1-expressing cells were apparently longer than GFP control cells, they were not statistically significant ( Figure 2c ), whereas Y405* expression was insufficient to reliably assess its effects. Expression of S1126* also increased the Euclidean distance traveled and cell velocity (Supplemental Figure 2a and b). We next examined the effects of ROCK1 mutants on adhesion using a Transwell dissociation assay (Doki et al., 1993) . All three ROCK1 mutants significantly increased the number of cells that had crossed and dissociated from the Transwell membrane (Figure 2d ), indicating reduced cell adhesiveness, a property associated with increased metastatic potential. Expression of S1126* was also sufficient to further increase dissociation of the highly metastatic MDA MB 231 breast cancer cell line in this assay (Supplemental Figure 2d) . Interestingly, the S1126* mutant had the greatest effects on cell contraction, morphological changes, motility and dissociation ( Figure 2 ) as well as inducing more prominent actin stress fibers and MLC phosphorylation ( Figure 1c ) relative to the other mutants. These observations indicate that somatic ROCK1 cancer (yellow) have an inserted C1 domain (dark blue). Asterisk indicates the position of amino-acid substitution. Drawn to scale. Plasmids expressing WT and K105G ROCK1 (pCAG MYC ROCK1) were previously described (Coleman et al., 2001) . Y405*, S1126* and P1193S were generated using QuikChange (Stratagene, Stockport, UK) site-directed mutagenesis according to the manufacturer's protocol. (b) MYC-tagged WT, K105G, Y405*, S1126* and P1193S were immunoprecipitated from transfected NIH3T3 cells as previously described (Coleman et al., 2001) . Upper panel immunoprecipitates were assayed for ROCK1 kinase activity at 30 1C for 10 min in a total volume of 50 ml containing 50 mM Tris/ HCl, pH 7.5, 0.1 mM EGTA, 0.1% (v/v) 2-mercaptoethanol, 10 mM MgCl 2 , 0.1 mM [g-32 P]ATP (2 Â 10 6 c.p.m./nmol) and 50 mM LIMKtide (lkkpdrkkrytvvgnpywma). The reaction was stopped by spotting onto p81 paper and submerging in 1% (v/v) orthophosphoric acid. The amount of phosphate incorporation was determined using Cerenkov counting. Results are mean ± s.e.m. activity relative to WT (n ¼ 3, *Po0.05 by t-test). Lower panel, lysates were separated by SDS-polyacrylamide gel electrophoresis and immunoblotted with anti-MYC antibody. Arrows indicate ROCK1 proteins.~, nonspecific bands. (c) MYC-tagged WT, S1126* and P1193S were immunoprecipitated from transfected HEK293 cells and assayed as described above either without or with the addition of GTP-loaded RhoA. Results are mean±s.e.m. activity relative to activity in the absence of RhoA-GTP (n ¼ 3, *Po0.05 relative to absence of RhoA-GTP by t-test). (d) Representative immunofluorescence confocal images of serum-starved NIH-3T3 fibroblasts stained for actin (top panels) and phosphorylated myosin light chain (pMLC; bottom panels). Cellular nuclei, stained with DAPI, are shown in blue. Arrows indicate cells positive for MYC-tag ROCK1. Scale bars represent 50 mm. After transfection, cells were serumstarved overnight and then fixed and stained as previously described (Coleman et al., 2001) . Confocal images were obtained using an Olympus FV1000 (Olympus, Southend, UK) using a 60 Â oil-immersion objective.
mutations that result in increased kinase activity also promoted changes in cell morphology, increased motility and decreased adhesion.
Next, we addressed how these mutations lead to increased ROCK1 activity. ROCK1 is an unusual AGC kinase family member as its kinase domain assumes an active conformation without activation loop phosphorylation (Jacobs et al., 2006) . Instead, ROCK1 activity is restrained by its inhibitory C terminus; relief from autoinhibition results from Rho-GTP binding or by caspase cleavage at a C-terminal site (Ishizaki et al., 1997; Coleman et al., 2001) . All three ROCK1 mutations affect the C terminus, suggesting that they activate by disrupting inhibitory interactions between N-and C-terminal domains. Despite the role of the C terminus in ROCK1 autoinhibition, the kinaseinteracting regions had not been previously mapped. We probed a 21-mer peptide array (Figure 3a ) compris- . Cells were co-transfected in the ratio of 1:2 of GFP and ROCK1 constructs and plated into a glass bottom six-well plate in complete medium. Three hours after nucleofection, the medium was replaced with reduced serum (3.3% fetal bovine serum, FBS) medium. Three bright field and GFP time lapse images were captured for each treatment at every 2 min for 20 h. Individual cell motility was analyzed using Metamorph (Wokingham, UK) and Image J. Mean cumulative track lengths ± s.e.m. (n ¼ 4, right panel). Statistical comparison performed by analysis of variance (ANOVA) followed by Dunnett's multiple comparison test (*Po0.05 vs GFP; **Po0.01 vs GFP). (d) Mean number of dissociated cells following chemotaxis of ROCK1-transfected NIH 3T3 cells through Transwell membranes. Cells were co-transfected in the ratio of 1:2 of GFP and ROCK1 constructs and incubated within an 8 mm pore Transwell insert for 3 h. Growth medium was then aspirated from the Transwell insert and replaced with serum-free medium, and the insert was placed in a fresh well containing medium containing 10% FBS and incubated for 18 h. The number of GFP-positive cells dissociated from the membrane were counted from three independent 20 Â fields. Results are mean ± s.e.m. (n ¼ 4), statistical analysis performed by ANOVA followed by Dunnett's multiple comparison test (**Po0.01 vs GFP).
ing amino acids 1-75 containing the N-terminal dimerization region and amino acids 853-1354 of the C terminus with [ 35 S]-labeled ROCK1 kinase domain (amino acids 1-404). As expected, the probe bound to the ROCK1 N-terminal residues 27-75 that mediate kinase dimerization (Figure 3b, Supplementary Figure  3a ) (Jacobs et al., 2006) . In addition, the kinase domain strongly bound four C-terminal regions (Figures 3a  and b ; regions 2d, 2f, 2h and 2i), indicating that potentially there are multiple sites engaged in kinase regulation. Region 2d overlapped with the latter half of the Rho-binding domain. The first segment of the split pleckstrin homology (PH) domain contained regions 2f, whereas the second segment overlapped with 2i. Binding region 2h was contained within the cysteine-rich C1 domain. Kinase binding to the region containing P1193 (2g) was weak though detectable. To further characterize these kinase-binding regions, we expressed FLAG-tagged protein fragments in Escherichia coli and tested their abilities to bind recombinant GST-ROCK1 kinase domain (200 ng) spotted onto nitrotrocelluose membranes. Regions 2g, 2h and 2i significantly bound Recombinant GST-ROCK1 kinase domain (amino acids 1-535; 200 ng) was spotted directly on nitrocellulose and blocked in 5% milk/TBS, and then incubated with equivalent amounts of indicated recombinant protein fragments in 5% milk/TBS for 18 h at 4 1C. Membranes were washed and then probed with rabbit anti-GST and mouse anti-FLAG antibodies to detect ROCK1 and FLAG-labeled binding proteins, respectively. Infrared fluorophore-conjugated secondary antibodies were detected at 700 and 800 nm using a Li-Cor Odyssey. Surface plot indicates signal intensity for each condition. Data represent mean±s.e.m. of fold increase in protein binding over blank from three to nine replicates. Statistical analysis calculated by analysis of variance followed by Bonferroni's multiple comparison test (**Po0.01 vs blank or indicated group; ***Po0.001 vs blank).
ROCK1 kinase domain, whereas 2d binding was detectable but did not achieve significance (Figure 3c ). Region 2f could not be tested because of protein insolubility. The P1193S mutation significantly reduced kinase binding by over 30% (Figure 3c ). To test the role of these domains in kinase regulation, representative 21-mer peptides from each binding region were synthesized and tested in an IMAP fluorescencepolarization ROCK1 kinase assay. Kinase activity was significantly inhibited by 2f and 2g peptides (Figure 4a ), whereas the P1193S mutation significantly reduced kinase inhibition relative to WT 2g (Figure 4b ). These results indicate that multiple surfaces in the ROCK1 C terminus likely contribute to kinase-domain binding and regulation. These interactions range from relatively weak and non-regulatory (2d) to strong and inhibitory (2g). In addition to the significant contribution of region 2g that contains P1193, region 2h appears to be an important kinase-binding region, possibly contributing to stabilizing N-and C-terminal interactions.
The data presented above make it easy to conceive how the Y405* and S1126* mutants, which respectively lack all or most of the kinase-interacting and autoinhibitory regions 2f, 2g and 2h, would be constitutively activated. Given the high degree of conservation between the ROCK1 and ROCK2 PH-C1-PH domains in general, and the 2f, 2g and 2h regions in particular (Supplemental Figure 3b) , the kinase-interacting and inhibitory regions were modeled onto the NMR solution structures of the PH-C1-PH domains (Wen et al., 2008) (Figures 4c and d) . In addition to directly affecting kinase binding and inhibition, as can be seen in Figure 4c , P1193 breaks a short a-helix before a b-sheet that leads on toward the C1 domain. We predict that the P1193S mutation does not provide the appropriate a-helix break, and as a consequence will disorder the split PH domain and likely disrupt the C1 domain. In addition, the structural rigidity provided by a proline residue would be reduced when substituted with a serine residue, which might result in less ordered folding. These alterations would result in inefficacious kinase inhibition. In addition, modeling of the 2f, 2g and 2h regions reveals that they form multiple surfaces located directly opposite to a series of charged lysine and arginine residues that cooperate to mediate lipid interaction and to orientate ROCK PH-C1-PH domains in membrane bilayers BPA (Wen et al., 2008) (Figure 4d) . As a result, the critical kinase interaction and inhibitory domains are exposed to the cytosol and are thus accessible for interaction and inhibition of the ROCK catalytic domain. These results show that although the ROCK1 somatic mutations affect the gene product differently, they all have a common mechanism of kinase activation: attenuation of the C-terminal inhibitory function.
In summary, the three ROCK1 mutations, Y405*, S1126* and P1193S have enhanced kinase activity, promote contraction, increase motility and decrease adhesion; indicating that these mutations are all constitutively active, consistent with them being active cancer drivers. These kinase mutations associated with cancer have revealed two ROCK1 mutants similar to previously characterized activating deletions (caspasecleaved active form (Coleman et al., 2001) and an experimentally derived form (Itoh et al., 1999) ). In addition, a novel activating single amino-acid substitution was identified revealing new information about ROCK1 regulation. Mapping of the C-terminal kinase interacting regions and structural modeling has revealed that ROCK1 likely keeps kinase activity in check through interactions with multiple surfaces.
Three somatic mutations have also been described in the ROCK2 gene in human cancers; a T to C transversion at position 3508 in the LB2518 malignant melanoma cell line that results in an S1194P substitution (equivalent to S1162 in ROCK1) in the first PH domain, insertion of A at 3518-3519 in the CP50-MEL-B malignant melanoma cell line resulting in a frameshift and termination at Y1174* (equivalent to Y1142 in ROCK1) in the first PH domain, and deletion of T at 412 resulting in a frameshift and termination at W138* in a primary stomach carcinoma (http://www.sanger. ac.uk/cgi-bin/genetics/CGP/cosmicsearch?_q ¼ rock2). Given the results of this study, the clustering of the Y1174* and S1194P mutations in the first PH domain suggests that they would be activating mutations, although the W138* mutation retains little of the kinase region.
There are numerous examples of kinase activation by cellular proteolysis (Bokoch, 1998) , as exemplified by caspase cleavage of ROCK1 (Coleman et al., 2001 ) and granzyme B cleavage of ROCK2 (Sebbagh et al., 2005) . The organization of ROCK1 and ROCK2 domains containing N-terminal kinase domains and C-terminal autoinhibitory domains lends them to activation by proteolysis or by mutations that result in premature termination. Therefore, it could be predicted that other kinases organized in a similar manner would also be subjected to activating mutations that affected Cterminal regulatory regions. Indeed, the Cdc42-regulated MRCKa (aka CDC42BPA), which has a similar role in actin cytoskeleton regulation as ROCK1 and ROCK2, has an example of a frameshift and termination at K697* in the HCC1395 breast ductal carcinoma cell line that removes autoinhibitory C1 and PH-like domains (Tan et al., 2001) . Interestingly, four nonsynonymous mutations were identified for MRCKb (aka CDC42BPB), all of which occur C terminal to the kinase domain and therefore are potentially activating, with the mutation most likely to be activating consisting of a frameshift and termination at R1092* found in an intestinal adenocarcinoma tumor.
The increased activity of the ROCK1 mutations suggests independence from the upstream regulator Rho, similar to Ras-independent activating B-Raf mutations. Although the rate of ROCK1 mutations was low, these results justify screening a larger set of cancers to determine a more representative rate and identify additional mutations. Furthermore, these observations additionally validate the value of highthroughput sequencing for identification of new cancer Figure 4 ROCK1 kinase-binding regions inhibit kinase activity (a) Representative peptides corresponding to the following spots on the peptide array 2d (d17), 2f (f16), 2g (g15), 2h (h12) and 2i (i12) were synthesized and tested for ROCK1 inhibition. Buffer containing 10 mM Tris/HCl pH 7.2, 10 mM MgCl 2 , 0.05% NaNO 3 and 0.1% phospho-free bovine serum albumin and supplemented with 100 nM fluorescein-tagged peptide substrate derived from S6 Kinase (5FAM-AKRRRLSSLRA), 100 mM ATP and 100 mM of the indicated peptide in 50 ml was incubated for 30 min at room temperature. IMAP binding reagent diluted 1:400 in the buffer described above was added to each well (65 ml), incubated for 30 min at room temperature and then fluorescence polarization read with a Tecan Safire2 multimode microplate reader by exciting the sample at 470 nm and measuring emission at 525 nM. (b) Fluoresence polarization assay of ROCK1 inhibition by 100 mM of 2g, 2g P1193S and Y-27632. Data represent mean kinase activity ± s.e.m. from two to five replicates expressed as a percent of control. Statistical analysis calculated by analysis of variance followed by Dunnett's multiple comparison test (*Po0.05; **Po0.01; ***Po0.001 vs control). (c) Ribbon diagram showing that P1193 (green) is located between an a-helix and a b-sheet in the PH domain (yellow). A part of the kinase-interacting region 2g is highlighted in orange. In full-length ROCK, the interrupting C1 domain would be expected to continue from the orange ribbon (2g) and rejoin the PH domain at the indicated residue in blue. Residues and domains modeled and rendered onto the ROCK2 PH structure (2rov) from PDB coordinates using Pymol. (d) Surface modeling of PH and C1 domains with predicted membrane orientation. ROCK1 binding and inhibitory domains 2 g (orange), 2f (brown) and 2h (light blue) modeled onto separately solved PH (yellow) and C1 (dark blue) structures of ROCK2 (PDB file 2rov and 2row, respectively). Location of P1193 is indicated in green. Residues highlighted in red mediate lipid binding (Wen et al., 2008) . Charged head groups of the inner leaflet of a phospholipid bilayer are drawn in gray. Dashed lines indicate the expected structural attachments between the PH and C1 domains. Structures were modeled and rendered in Pymol.
genes, and for providing valuable unbiased insight into protein regulation and function.
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